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a b s t r a c t
Mu opioid receptor selective antagonists are highly desirable because of their utility as pharmacological
probes for receptor characterization and functional studies. Furthermore, the mu opioid receptors act as
an important target in drug abuse and addiction treatment. Previously, we reported NAP as a novel lead
compound with high selectivity and affinity towards the mu opioid receptor. Based on NAP, we have syn-
thesized its derivatives and further characterized their binding affinities and selectivity towards the
receptor. NMP and NGP were identified as the two most selective MOR ligands among NAP derivatives.
In the present study, molecular modeling methods were applied to assess the dual binding modes of NAP
derivatives, particularly on NMP and NGP, in three opioid receptors, in order to analyze the effects of
structural modifications on the pyridyl ring of NAP on the binding affinity and selectivity. The results
indicated that the steric hindrance, electrostatic, and hydrophobic effects caused by the substituents
on the pyridyl ring of NAP contributed complimentarily on the binding affinity and selectivity of NAP
derivatives to three opioid receptors. Analyses of these contributions provided insights on future design
of more potent and selective mu opioid receptor ligands.
Published by Elsevier Ltd.
1. Introduction
G protein-coupled receptors (GPCRs), one of the largest groups
of membrane proteins in the human genome,1 play important roles
in many physiological processes, such as signal transduction, neu-
rotransmission, immune defense, and cellular metabolism.2,3 Opi-
oid receptors belong to the rhodopsin-type family A of GPCRs,
which are widely distributed in the central nervous system
(CNS).4 The opioid receptor family includes four subtypes: l-opioid
receptor (MOR), j-opioid receptor (KOR), d-opioid receptor (DOR)
and nociceptin receptor (NOP).5–7 Among these four receptors,
MOR, KOR, and DOR share fairly high amino acid sequence similar-
ity among them. Their crystal structures have been reported
recently,8–14 which allow us to study their structural characteris-
tics at the atomic level. Moreover, MOR, KOR, and DOR are also
involved in many common physiological processes, such as pain
perception, depression, anxiety, and drug abuse and addiction.15–
18 It has been demonstrated that the MOR plays primary role in
controlling antinociception, and the DOR is linked to mood related
disorders,19,20 while the KOR is known to cause dysphoric effects as
well as anxiety.21–23 The demonstration of structural features and
physiological symptoms of three opioid receptors make them
become promising drug targets for treatment of pain, depression,
and drug abuse and addiction.24
MOR agonists have been pharmaceutically favored ligands
owing to MOR’s primary role in pain management system. Tradi-
tionally, agonist mediated opioid function can be characterized
as such only when their effects are competitively reversed by
MOR antagonists.16,25 Thus, development of MOR selective antago-
nists has also become imperative in opioid research. More spe-
cially, non-peptidyl, selective, and potent MOR antagonists are
highly desired for functional characterization of MOR.26–28 Apart
from being a pharmacological tool, MOR antagonists may also play
a critical role in treatment of substance abuse and addiction.16,18
Some partially selective MOR antagonists including naloxone, nal-
trexone and nalmefene have been reported to have beneficial
effects including decrease in drug craving and relapse for opiate
addicts as well as in treatment of alcoholism.29–32 Although these
MOR antagonists are promising, some serious side effects have also
been observed. Besides causing depression and dysphoria,26–28,33–35
these drugs have also been reported to cause higher incidence of
overdoses and suicides among the opiate addict patients29,31,32,36
http://dx.doi.org/10.1016/j.bmc.2017.03.005
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due to their affinity to the DOR and KOR and low selectivity to the
MOR. Hence, it is plausible that such side effects could be mitigated
by development of more selective MOR antagonists.
Previously, we reported a series of naltrexone-derived ligands
of opioid receptors. Experimental characterizations, both in vitro
and in vivo, of these compounds led us to a particularly potent
and selective compound NAP (Fig. 1a), our first generation MOR
antagonist. Radioligand binding assays of NAP suggested that it
had high binding affinity and selectivity towards the MOR when
compared to the KOR and DOR (MOR Ki 0.37 nM, MOR/
KOR  164, MOR/DOR  750).37 Besides, we also reported charac-
terization of molecular interactions involved in binding of NAP in
the MOR, KOR, and DOR models derived from their respective X-
ray crystal structures through molecular modeling studies. These
molecular modeling results indicated that the morphinan moiety
of NAP located in the ‘message’ interacting region of the receptors
while the heterocyclic pyridyl ring of NAP interacted with either of
the two ‘address’ domains of the receptors. The amino acid resi-
dues of the latter domain were non-conserved among the opioid
receptors, which conferred its selectivity for the MOR over the
KOR and DOR.38
Based on the structure of lead compound NAP and its binding
modes in the MOR, KOR, and DOR, our second generation MOR
antagonists were designed, synthesized, and characterized.39
Among these NAP derivatives, NMP and NGP (Fig. 1b and c) were
identified as the two most selective MOR antagonists, which
showed comparable binding affinity, selectivity, and efficacy to
NAP. In this paper, docking studies and molecular dynamics simu-
lations were applied to characterize the binding modes of NMP and
NGP with three opioid receptors in order to understand how
change of substituent properties or their position in the pyridyl
ring would lead to similar ligand binding affinity and selectivity.
These computational studies coupled with experimental data
may give further insights on ‘address’ domain of opioid receptors
and provide valuable information for developing more potent
and selective MOR antagonists.
2. Results and discussion
2.1. Analysis of the ‘address’ moiety of NAP derivatives
The binding affinity and selectivity of NAP, NMP, and NGP to the
MOR, KOR, and DOR together with the pKa values of nitrogen atom
on their pyridyl rings in each compound were summarized in
Table 1. The pKa values were estimated by software ACD/I-lab
2.0 (Advanced Chemistry Development, Inc.). It is well-known that
pKa value can be used to measure the capability of a molecule or
ion to keep a proton (H+) at its ionization center. The greater the
pKa value, the stronger the ability to keep a proton, or, conversely,
the lower the value, the weaker to keep a proton.40 As the pKa of
pyridine is about 5.25,41 the pyridine would be mainly in unionized
form at the physiological pH. However, substitutions on the pyri-
dine ring can change the capability of nitrogen atom on pyridine
to keep a proton. That is, an electron donating substitution on pyr-
idyl ring would strengthen such ability, while an electron with-
drawing group on pyridyl ring would weaken it. In NAP, the
Fig. 1. The chemical structures of NAP (a), NMP (b), and NGP (c). The chemical structures with atom notation were derived from the complexes after molecular dynamics
simulations.
2464 H. Wang et al. / Bioorganic & Medicinal Chemistry 25 (2017) 2463–2471
amide linker group was an electron withdrawing group to the pyr-
idyl ring, which would weaken the capability of nitrogen atom on
pyridyl ring to keep a proton. Hence, NAP was more likely to stay
predominantly in its unionized form at the physiological pH.
As discussed in our previous studies, the amide linker would
provide the pyridyl ring of NAP enough flexibility to interact with
either of the two ‘address’ domains of the three opioid receptors.38
We defined these two interaction regions as site A and site B
(Table 2). Site A included a positively charged residue Lys3036.58
and site B had a negatively charged residue Glu2295.35 in the
MOR. The pyridyl ring of NAP preferred to interact with the site
A of the MOR owing to the p-p stacking interaction between the
aromatic pyridyl ring and residue Trp3187.35 and electrostatic
interaction between the electron rich nitrogen atom of pyridyl ring
and residue Lys3036.58. Since there was no positively charged resi-
dues in the KOR and DOR that could interact with electron rich
nitrogen atom of pyridyl ring (Table 2), the binding affinities of
NAP with KOR and DOR were much lower than that of NAP with
the MOR.38,39 Therefore, we may conclude that both the aromatic-
ity of the pyridine and the substituent at the pyridyl ring of NAP
interacting with the residues in the ‘address’ domains influenced
the binding of NAP to all three opioid receptors.
From Table 1, it could also be observed that both NMP and NGP
had comparable binding affinity and selectivity to NAP in all three
opioid receptors. Comparing NMP with NAP, there was an extra
methyl group on the pyridyl ring of NMP, which could lead to a
steric effect in the binding pocket. To NGP, the addition of a glycine
group to the amide linker would further increase the length of the
space between the ‘message’ and ‘address’ moieties. Besides, as the
methyl group was an electron donating group to the pyridyl ring of
NMP, the capability of the nitrogen atom on the pyridyl ring of
NMP to keep a proton would be stronger than that of NAP. While
the amide linker group was an electron withdrawing group to
the pyridyl ring of NGP, which was the same to that of NAP, conse-
quently, the capability of the nitrogen atom on the pyridyl ring of
NGP should be almost equal to that of NAP. The pKa values of nitro-
gen atom on pyridyl ring of NAP, NMP, and NGP in Table 1 also con-
firmed our analyses. In all, besides electrostatic effect, other effects,
such as steric and hydrophobic effects caused by the substituent,
may influence the binding of NMP and NGP to the receptors.
Hence, in order to further understand how these substituents
affected the binding modes and affinities of NMP and NGP, docking
exercises and molecular dynamics simulations were applied.
2.2. Docking studies of NMP and NGP
In our previous studies, NAP was docked into the well-known
antagonist binding pockets of the MOR, KOR, and DOR,38 which
had been proved by various opioid antagonists.37,42–44 In the cur-
rent study, GOLD docking algorism45 was again applied to dock
both NMP and NGP into the same site of three opioid receptors
in the similar fashion to NAP. The optimal docking poses of NMP
and NGP in each receptor were chosen based on the highest
CHEM-PLP and HINT scores, and these optimal docking results
were displayed in Figs. 2 and 3.
It could be seen from Figs. 2 and 3 that the morphinan moiety of
NMP and NGP occupied the similar ‘message’ domain to that of
NAP.38 That is, the morphinan moiety was housed within a con-
served hydrophobic pocket formed by residues Met3.36, Trp6.48,
His6.52, and Tyr7.43 in all three receptors. Typically, piperidine qua-
Table 1
The binding affinity and selectivity of NAP, NMP, and NGP together with the pKa value of nitrogen atom on pyridyl ring in each compound.
Compounds R Ki (nM) Selectivity ratio pKa
MOR KOR DOR MOR/KOR MOR/DOR
NAP 0.37 ± 0.07 60.72 ± 5.58 277.51 ± 7.97 164 750 3.56 ± 0.1
NMP 0.58 ± 0.25 96.7 ± 12.2 273.6 ± 1.8 166 472 3.81 ± 0.18
NGP 0.73 ± 0.59 203.2 ± 67.0 526.1 ± 78.3 278 719 3.49 ± 0.1
Table 2
Plausibly critical residues in the ‘address’ domains along with their dominant
chemical feature.38
Receptor Site A Site B
MOR Lys3036.58 and Trp3187.35 Thr2255.31 and Glu2295.35
Positive and Hydrophobic Hydrophobic and Negative
KOR Glu2976.58 and Tyr3127.35 Tyr2195.31 and Asp2235.35
Negative and Hydrophobic Hydrophobic and Negative
DOR Trp2846.58 and Leu3007.35 Ser2065.31 and Asp2105.35
Hydrophobic Hydrophobic and Negative
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ternary ammonium nitrogen formed ionic interactions with resi-
due Asp3.32, and the tetrahydrofuran oxygen of the morphinan
moiety formed hydrogen bond with residue Tyr3.33. Similar to
NAP, due to the flexibility caused by the amide linker, the pyridyl
moiety of NMP and NGP may also adopt two different conforma-
tions, which could engage two different ‘address’ domains in each
opioid receptor: site A and site B (Table 1). Interestingly, it seemed
that from the docking study the pyridyl ring of NMP interacted
with site B of MOR and KOR, but occupied site A of DOR while
the pyridyl ring of NGP formed interactions with site A of MOR,
KOR and site B of DOR (Fig. 3).
2.3. Molecular dynamics simulations of NMP and NGP within the
opioid receptors in a lipid bilayer membrane system
To further understand the binding modes of NMP and NGP in all
three opioid receptors and analyze the interactions between the
‘address’ interaction region of three opioid receptors and the pyri-
dyl ring of NMP and NGP in more detailed fashion, and more
importantly, to provide possible explanation on the difference of
docking site preference among NAP, NMP, and NGP, molecular
dynamics (MD) simulations were performed on MOR-NMP, KOR-
NMP, DOR-NMP, MOR-NGP, KOR-NGP, and DOR-NGP complexes
to optimize these binding modes obtained from the docking stud-
ies. For the purpose of obtaining stable systems, 10 ns MD simula-
tions on the six systems in a lipid bilayer membrane system
enclosed in a water box were carried out. After that, the root-
mean-square deviation (rmsd) values of all the protein backbone
atoms based on the respective starting structures were calculated
to ensure the stability of all the systems, and the results were dis-
played (Fig. 4). It seemed that the rmsd values of the backbone
atoms in all systems remained stable after 5 ns of MD simulations.
And the average rmsd values of MOR-NMP, KOR-NMP, DOR-NMP,
MOR-NGP, KOR-NGP, and DOR-NGP complexes were 1.98, 1.33,
1.72, 1.57, 1.38, and 1.56 Å, respectively. It has been reported that
the rmsd value of a system smaller than 3.0 Å would indicate that
the system achieved dynamics equilibrium.46–48 Therefore, it can
be concluded that the six systems were stabilized after 10 ns MD
simulations.
The binding modes of MOR-NMP, MOR-NGP, KOR-NMP, KOR-
NGP, DOR-NMP, and DOR-NGP complexes after 10 ns MD simula-
tions were displayed in Figs. 5–7 respectively. These figures
showed that the ‘message’ moiety morphinan of NMP and NGP
remained in the ‘message’ domains in the receptors, which was
consistent with the docking results. And the ‘address’ moiety pyr-
idyl ring of NMP and NGP in MOR, KOR, and DOR interacted with
the ‘address’ binding domain, but the binding site was different
from the docking results. For example, the pyridyl ring of NMP
interacted with site B of the MOR from the docking study while
it now resided in site A of the MOR after MD simulation (see
detailed analyses in the following sections). The residues located
at site A or site B in the MOR, KOR, and DOR were showed in
Table 3. In this table, amino acid residues contributing significantly
to binding of the pyridyl ring of NAP, NMP, and NGP were dis-
played in bold.
2.4. Analysis of NMP and NGP in the ‘address’ domain of the MOR after
MD simulations
In the MOR-NMP complex, the methyl group on the pyridyl ring
of NMP could strengthen the capability of nitrogen atom on pyridyl
ring to keep a proton while two positively charged residues
Lys2335.39 and Lys3036.58 in site A of the MOR were not close
enough. The electrostatic expelling force between the pyridyl ring
of NMP and residues Lys2335.39 and Lys3036.58 probably was not
strong enough to influence the binding of the pyridyl ring of
Fig. 2. NMP conformation (yellow balls and sticks) in MOR site B (a), KOR site B (b), and DOR site A (c) with highest CHEM-PLP and HINT scores from docking studies.
Fig. 3. NGP conformation (white balls and sticks) in MOR siteA (a), KOR site A (b), and DOR site B (c) with highest CHEM-PLP and HINT scores from docking studies.
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NMP in site A. In consequence, the pyridyl ring of NMP still pre-
ferred to interact with Trp3187.35 in site A of the MOR (Fig. 5a).
Meanwhile, this methyl group also could result in steric hindrance
effect, leading to the pyridyl ring of NMP moving slightly away
from residues Lys2335.39, Val3006.55, and Lys3036.58 (Table 4) com-
pared to that of NAP. Consequently, the electrostatic interactions
with residues Lys2335.39 and Lys3036.58 and the hydrophobic inter-
action with residue Val3006.55 from the pyridyl ring of NMP were
relatively weaker than those in the MOR-NAP complex. On the
other hand, such a movement would lead to the distance decrease
between the pyridyl ring of NMP and residue Trp3187.35 which fur-
ther strengthened the p-p stacking interaction between the aro-
Fig. 4. The root-mean-square-deviation (rmsd) of the protein backbone atoms of the six complexes relative to the respective starting structures.
Fig. 5. Binding modes of MORsite A-NMP (a) and MORsite B-NGP (b) complexes with key residues in the binding pocket after 10 ns MD simulations.
Fig. 6. Binding modes of KORsite A-NMP (a) and KORsite B-NGP (b) complexes with key residues in the binding pocket after 10 ns MD simulations.
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matic pyridyl ring of NMP and residue Trp3187.35. In all, NMP
showed high binding affinity to site A of the MOR after MD
simulations.
In the MOR-NGP complex, the glycine linker increased the space
between morphinan skeleton and the pyridyl ring of NGP, which
made it difficult to accommodate the pyridyl ring of NGP in site
A of the MOR. Conversely, site B of the MOR had a hydrophobic
pocket including residues Leu219ECL2 and Phe221ECL2, which could
form favorable hydrophobic interactions with the aromatic pyridyl
ring of NGP. Hence, the pyridyl ring of NGP seemed to prefer site B
of the MOR. Meanwhile, the amide linker was also an electron
withdrawing group to the pyridyl ring of NGP, which made the
electrostatic interaction between the pyridyl ring and the residue
Glu2295.35 in MOR-NGP complex almost equal to that in MOR-
NAP complex. As the glycine group would increase the length of
the space between morphinan skeleton and pyridyl ring of NGP,
which could result in the pyridyl ring of NGP moving close to resi-
dues Leu219ECL2 and Phe221ECL2 but moving away from residue
Thr218ECL2 (Table 4). In consequence, the hydrophobic interactions
between the pyridyl ring of NGP and residues Leu219ECL2 and
Phe221ECL2 would be stronger than that in the MOR-NAP complex.
However, the hydrogen bonding between the nitrogen atom of the
pyridyl ring and residue Thr218ECL2 in MOR-NAP complex was
weakened in the MOR-NGP complex. Overall, NGP preferred to site
B of the MOR after MD simulations.
2.5. Analysis of NMP and NGP in the ‘address’ domain of the KOR after
MD simulations
Similar binding sites of the pyridyl ring of NMP in theMORwere
also observed in the KOR (Fig. 6). In the KOR-NMP complex, though
the nitrogen atom of the pyridyl ring of NMP had a relatively stron-
ger ability to keep a proton and a negatively charged residue
Glu2976.58 located at site A of KOR, the electrostatic interaction
between the pyridyl ring of NMP and residue Glu2976.58 was not
obvious within site A of the KOR due to the distance in between.
On the other hand, hydrophobic residues Ile2906.51, Phe2936.54,
and Ile2946.55 at site A of the KOR might form somehow weak
hydrophobic interactions with the pyridyl ring of NMP to accom-
Fig. 7. Binding modes of DORsite B-NMP (a) and DORsite A-NGP (b) complexes with key residues in the binding pocket after 10 ns MD simulations.
Table 3
The residues at site A or site B in MOR, KOR, and DOR.a
MOR KOR DOR
Site A Site B Site A Site B Site A Site B
NAP Lys2335.39 Thr218ECL2 Ile2906.51 Ser211ECL2 Val2816.55 Leu1253.29
Ile2966.51 Leu219ECL2 His2916.52 Leu212ECL2 Trp2846.58 Tyr1293.33
His2976.52 Thr220ECL2 Phe2936.54 Phe214ECL2 Leu3007.35 Leu200ECL2
Val3006.55 Phe221ECL2 Ile2946.55 Tyr2195.31 Ile3047.39 Phe202ECL2
Lys3036.58 Thr2255.31 Glu2976.58 Asp2235.35 Ser2065.31
Trp3187.35 Glu2295.35 Tyr3127.35 Lys2275.39 Asp2105.35
Ile3227.39 Lys2145.39
NMP Lys2335.39 Thr218ECL2 Ile2906.51 Ser211ECL2 Val2816.55 Leu1253.29
Ile2966.51 Leu219ECL2 His2916.52 Leu212ECL2 Trp2846.58 Tyr1293.33
His2976.52 Thr220ECL2 Phe2936.54 Phe214ECL2 Leu3007.35 Leu200ECL2
Val3006.55 Phe221ECL2 Ile2946.55 Tyr2195.31 Ile3047.39 Phe202ECL2
Lys3036.58 Thr2255.31 Glu2976.58 Asp2235.35 Ser2065.31
Trp3187.35 Glu2295.35 Tyr3127.35 Lys2275.39 Asp2105.35
Ile3227.39 Lys2145.39
NGP Ile2966.51 Thr218ECL2 Ile2906.51 Ser211ECL2 Val2816.55 Leu1253.29
His2976.52 Leu219ECL2 His2916.52 Leu212ECL2 Trp2846.58 Tyr1293.33
Val3006.55 Thr220ECL2 Phe2936.54 Phe214ECL2 Leu3007.35 Leu200ECL2
Lys3036.58 Phe221ECL2 Ile2946.55 Tyr2195.31 Ile3047.39 Phe202ECL2
Trp3187.35 Thr2255.31 Glu2976.58 Asp2235.35 Ser2065.31
Ile3227.39 Glu2295.35 Tyr3127.35 Lys2275.39 Asp2105.35
a The residues in Bold had key contributions to the pyridyl ring of NAP, NMP, and NGP binding.
2468 H. Wang et al. / Bioorganic & Medicinal Chemistry 25 (2017) 2463–2471
modate the ligand. Thus, comparing to its high binding affinity in
the MOR, NMP showed much lower affinity to the KOR.
The binding mode of NGP in the KOR was also similar to that in
the MOR. Comparing Fig. 6(b) with Fig. 5(b), it could be found that
residues Leu212ECL2, Phe214ECL2, and Asp2235.35 in the KOR were at
the conserved position of residues Leu219ECL2, Phe221ECL2, and
Glu2295.35 in the MOR. On the other hand, the electrostatic interac-
tion between the pyridyl ring in NGP and residue Asp2235.35 was
also an unfavorable distance due to the stretched conformation
of the ligand. In addition, the hydrophobic interactions between
the pyridyl ring in NGP and residues Leu212ECL2 and Phe214ECL2
in the KOR-NGP complex seemed weaker than those in the MOR-
NGP complex as reflected by the ligand-residue distance in Table 4.
Therefore, NGP also showed reasonable selectivity to the MOR over
the KOR.
2.6. Analysis of NMP and NGP in the ‘address’ domain of the DOR after
MD simulations
From Table 2 and Figs. 5–7, it was obviously that residues
Trp3187.35, Tyr3127.35, and Leu3007.35 were at a conserved position
of site A of the MOR, KOR, and DOR, respectively. As the bulkiness
and electronic properties of the side chain of Leu3007.35 (DOR) was
very different from those of Trp3187.35 (MOR) and Tyr3127.35
(KOR), the conformation of site A of the DOR could be different
from those of the MOR and KOR. For example, the space of site A
of the DOR was larger than those of the MOR and KOR (Figs. 5–
7). Thus, the binding sites of the pyridyl ring of NMP and NGP in
the DOR would be different from those in the MOR and KOR.
In DOR-NMP complex, the steric effect caused by the methyl
group on the pyridyl ring of NMP would make the pyridyl ring of
NMP moving away from Phe202ECL2 and Asp2105.35 and closer to
Leu200ECL2 in the site B of the DOR (Table 4). Consequently, only
some hydrophobic interaction (e.g. the pyridyl ring of NMP and
residue Leu200ECL2) existed between the pyridyl ring of NMP and
the site B of the DOR. Thus, comparing to the binding affinities of
NMP in the MOR and KOR, the binding affinity of NMP to the
DOR was the lowest.
As described above, the space of site A of DOR was large enough
to accommodate the pyridyl ring of NGP. At site A of the DOR, resi-
dues Trp2846.58 and Leu3007.35 could form relatively weak
hydrophobic interactions with the pyridyl ring of NGP (Table 4).
In result, NGP showed lower affinity to the DOR compared to that
in the MOR.
3. Conclusion
NAP derivatives, NMP and NGP, had shown a promising selec-
tivity profile at three opioid receptors. These two compounds have
been designed and synthesized based on ‘message-address’ con-
cept where the ‘address’ moiety of NMP and NGP was assumed
to determine selectivity. Docking studies of NMP and NGP on each
of three opioid receptors suggested presence of two distinct ‘ad-
dress’ domains in the receptors, each capable to interact with the
‘address’ moieties of NMP and NGP. Furthermore, the results of
the molecular dynamics simulations on NMP and NGP in three opi-
oid receptors showed that the binding of the pyridyl ring of NMP
and NGP with at least one of the two ‘address’ domains of the
receptors were generally stable.
In the MOR the two ‘address’ domains had distinct chemical
characteristics that site A had a positively charged residue while
site B had a negatively charged residue. Hence, the capability of
the nitrogen atom on the pyridyl ring of NMP and NGP to keep a
proton would affect the binding modes of NMP and MGP. More-
over, the steric effect caused by the methyl group on the pyridyl
ring of NMP and the increment of the spacer length between ‘mes-
sage’ and ‘address’ moieties caused by the glycine group on the
pyridyl ring of NGP also had impacts on their binding to the
MOR. This could be further evidenced by binding of NMP and
NGP with the KOR and DOR. Therefore, these results provided
the detailed information on receptor-ligand interactions and pre-
sented a strategy to modulate selectivity of NAP derivatives among
the opioid receptors. Upon our future molecular design to achieve
higher selectivity to the MOR over the DOR and KOR, the more
favored binding mode of each lead compound should be first con-
sidered over the less favored one. In those favored binding pockets,
unique chemical features of the side chains from the specific amino
acid residues interacting with the lead will be applied to design the
new substitutions of the 6-position ‘address’ portion of the next
generation ligands.
In conclusion, these studies provided as an example where
molecular modeling techniques, including molecular docking and
dynamics simulations, along with structure activity relationship
analyses can help explore receptor binding modes as well as guide
future ligand design.
4. Materials and methods
4.1. Preparing the structure of complexes
The X-ray crystal structures for MOR (4DKL8), KOR (4DJH9) and
DOR (4EJ412) were retrieved from PDB Data Bank at http://www.
rcsb.org. Each opioid receptor model was built by adding hydrogen
atoms, assigning Gasteiger-Hückel charges, and optimizing hydro-
gen coordinates by a 10,000 iteration minimization while holding
all heavy atoms as fixed under the Tripos forcefield (TFF) in
Sybyl-X 2.0. Small molecules were also sketched in Sybyl-X 2.0
Table 4
The measured distances between atoms on critical amino acid residues and atoms on
the ligands from NMP-MOR, NMP-KOR, NMP-DOR, NGP-MOR, NGP-KOR, and NGP-
DOR complexes.
Binding site of the ‘address’
moiety
Atom of residue Atom of
ligand
Shortest
distance (Å)
NMP and NAP in MORsite A NZ@Lys2335.39 N56@NAP 4.17
NZ@Lys2335.39 N56@NMP 5.63
CG1@Val3006.55 C57@NAP 3.94
CG2@Val3006.55 C52@NMP 5.69
NZ@Lys3036.58 N56@NAP 7.74
NZ@Lys3036.58 N56@NMP 7.30
CZ2@Trp3187.35 C55@NAP 6.00
CZ2@Trp3187.35 C54@NMP 4.44
NGP and NAP in MORsite B OG1@Thr218ECL2 N56@NAP 3.61
OG1@Thr218ECL2 N56@NGP 5.64
CB@Leu219ECL2 C57@NAP 4.20
CB@Leu219ECL2 C57@NGP 4.38
CE2@Phe221ECL2 C57@NAP 5.51
CE2@Phe221ECL2 C55@NGP 4.82
OE2@ Glu2295.35 C58@NAP 4.59
OE2@ Glu2295.35 C54@NGP 5.22
NMP in KORSite A CD@Ile2906.51 C54@NMP 4.77
CD2@Phe2936.54 C12@NMP 5.36
CG1@Ile2946.55 C57@NMP 5.70
OE1@Glu2976.58 N56@NMP 5.58
CD2@Tyr3127.35 C54@NMP 5.59
NGP in KORSite B CB@Leu212ECL2 C54@NGP 4.72
CE2@Phe214ECL2 C57@NGP 5.31
OD2@Asp2235.35 N56@NGP 5.21
NMP in DORSite B CD2@Leu200ECL2 C57@NMP 4.18
CE1@Phe202ECL2 C57@NMP 7.68
OD1@Asp2105.35 C54@NMP 6.10
NGP in DORSite A CH2@Trp2846.58 C55@NGP 4.20
CG@Leu3007.35 C58@NGP 4.95
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and their Gasteiger-Hückel charges were assigned before energy
minimization (10,000 iterations) under the TFF.49
4.2. Docking studies
GOLD 5.1,45 an automated genetic algorithm based docking pro-
gram was employed to perform the docking studies with standard
default settings, unless otherwise specified. The binding site was
defined to include all atoms within 10 Å of the c-carbon atom of
Asp3.32 of the three opioid crystal structures. Distance constraints
of 4 Å between the piperidine nitrogen of the ligands’ morphinan
nucleus and Asp3.32, and between the ligands’ tetrahydrofuran oxy-
gen and the phenolic oxygen of Tyr3.33 were included in the dock-
ing runs to reproduce ionic interaction between the acidic receptor
residue and quaternary nitrogen of the ligand and hydrogen bond
interaction between hydrogen bond donor tyrosine and hydrogen
bond acceptor tetrahydrofuran oxygen of the ‘morphinan’ skeleton
in the model. Based on the fitness scores and the binding orienta-
tion of each ligand within the binding cavity, the GOLD-docked
solutions were selected and merged into the receptor. The interac-
tions between ligand and receptor within the binding pocket were
optimized; clashes and strain energy were removed by energy
minimizing the receptor-ligand structure complexes (1000 itera-
tions under TFF) in Sybyl-X 2.0. After that, HINT algorism was
applied to analyze the hydropathic interactions between ligand
and receptor.50
4.3. Building the lipid membrane
VMD 1.9.151 was applied to prepare lipid membrane embedded
receptor-ligand ionized water box system for molecular dynamics
(MD) simulations. The Coordinate (pdb) and connectivity files (psf)
were generated for receptor-ligand complex using the psfgen mod-
ule. The VMD membrane module was employed to create a lipid
bilayer of POPC (1-Palmitoyl-2-oleoylphosphatidylcholine). Orien-
tation of protein in membrane (OPM)52 server is used to orient the
receptor within the lipid bilayer. This was followed by addition of
30 Å of water layers to both sides of membrane at the vertical axis,
using Solvate plugin. All the waters and POPC molecules at a dis-
tance of 0.65 Å or less from the receptor-ligand complex were then
deleted followed by deletion of waters within the POPCmembrane.
The water system was then ionized to 0.15 M of NaCl by the
Autoionize plugin. The ligand parameter and topology files were
obtained from Paramchem server.53
4.4. Molecular dynamics simulation
All molecular modeling simulations were performed using
NAMD 2.8.54 All MD simulations were carried out in four stages.
In the first stage, equilibration of the fluid-like lipid bi-layer was
performed via minimization (1000 iterations) followed by NPT
equilibration (pressure equilibration) of the lipid tails for a period
of 0.5 ns. Simulations were carried out using the CHARMM force
field with CHARMM22 parameters for protein, CHARMM27 param-
eters for lipids and CMAP corrections for proline, glycine and ala-
nine dipeptides55 with a time-step of 2 femtoseconds (fs).
Periodic boundary conditions were employed, and Particle Mesh
Ewald (PME) summation was used to calculate long-range electro-
static interactions. Non-bonded interactions were calculated with
a smooth cutoff between 10 and 12 Å with a frequency of 1 fs. Con-
stant pressure and temperature at 310 K was maintained via Lan-
gevin dynamics. In the second stage, an NPT equilibration of the
system was run for a period of 1 ns with harmonic constraints
placed on protein, ligand and crystallographic water atoms
(5 kcal/(mol-Å)) while keeping all the parameters same as earlier.
The harmonic restraint was released in stage 3 and the entire sys-
tem was equilibrated using the NVT canonical ensemble for a fur-
ther 1 ns. The final production run was conducted using an NVT
ensemble where the whole system was equilibrated for 10 ns.
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